Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALEC

Alector Inc

Oct 24 • 04:00PM ET

1.50

+0.03 2.04 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN IONS VRTX SGMO SAGE ACAD LLY GILD AVXL

| Held by: VTI VXF IWM VTWO IWN IBB SCHA VHT IWC PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.17	Insider Own	24.71%	Shs Outstand	101.21M	Perf Week	-50.66%
Market Cap	151.82M	Forward P/E	-	EPS next Y	-0.81	Insider Trans	-0.81%	Shs Float	76.20M	Perf Month	-48.81%
Enterprise Value	-115.98M	PEG	-	EPS next Q	-0.41	Inst Own	63.70%	Short Float	6.78%	Perf Quarter	-14.77%
Income	-115.29M	P/S	1.87	EPS this Y	-25.78%	Inst Trans	-4.44%	Short Ratio	2.35	Perf Half Y	31.58%
Sales	81.13M	P/B	2.13	EPS next Y	47.79%	ROA	-24.87%	Short Interest	5.17M	Perf YTD	-20.63%
Book/sh	0.70	P/C	0.49	EPS next 5Y	28.58%	ROE	-103.98%	52W High	6.14 -75.57%	Perf Year	-68.09%
Cash/sh	3.04	P/FCF	-	EPS past 3/5Y	-39.73% 6.31%	ROIC	-113.30%	52W Low	0.87 72.41%	Perf 3Y	-83.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-21.40% 36.50%	Gross Margin	88.49%	Volatility	12.43% 8.45%	Perf 5Y	-84.52%
Dividend TTM	-	EV/Sales	-1.43	EPS Y/Y TTM	35.46%	Oper. Margin	-160.25%	ATR (14)	0.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.78	Sales Y/Y TTM	46.78%	Profit Margin	-142.10%	RSI (14)	26.86	Recom	3.11
Dividend Gr. 3/5Y	- -	Current Ratio	3.78	EPS Q/Q	23.99%	SMA20	-47.88%	Beta	0.99	Target Price	2.20
Payout	-	Debt/Eq	0.55	Sales Q/Q	-47.80%	SMA50	-45.86%	Rel Volume	3.01	Prev Close	1.47
Employees	238	LT Debt/Eq	0.43	Earnings	Aug 07 AMC	SMA200	-16.64%	Avg Volume	2.20M	Price	1.50
IPO	Feb 07, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.98% 180.73%	Trades		Volume	6,626,212	Change	2.04%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-22-25	Downgrade	TD Cowen	Buy → Hold
Oct-22-25	Downgrade	Mizuho	Outperform → Neutral	$1.50
Oct-22-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-22-25	Downgrade	BTIG Research	Buy → Neutral
Jul-28-25	Upgrade	Mizuho	Neutral → Outperform	$3.50
Dec-17-24	Downgrade	Mizuho	Outperform → Neutral	$9 → $2.50
Dec-16-24	Downgrade	Stifel	Buy → Hold	$4
Dec-04-24	Downgrade	BofA Securities	Neutral → Underperform	$9 → $1
Nov-29-24	Reiterated	H.C. Wainwright	Buy	$35 → $7
Nov-26-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$10 → $3
Dec-14-23	Upgrade	Stifel	Hold → Buy	$8 → $15
Dec-12-23	Initiated	Deutsche Bank	Buy	$12
Sep-25-23	Initiated	Goldman	Sell	$4
Sep-22-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$24 → $12
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27 → $13
Jul-07-22	Initiated	Mizuho	Buy	$15
Apr-13-22	Initiated	Goldman	Sell	$9
Mar-08-22	Downgrade	Stifel	Buy → Hold	$32 → $18

Show Previous Ratings

Oct-22-25 07:22AM	Alector dementia drug, partnered with GSK, fails in key study (BioPharma Dive) -49.84%
Oct-21-25 04:05PM	Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update (GlobeNewswire)
Sep-16-25 08:00AM	Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs (GlobeNewswire) -6.76%
Sep-12-25 09:09AM	Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock? (Zacks)
Aug-28-25 08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
09:55AM	Loading…
Aug-22-25 09:55AM	After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright (Zacks) +11.01%
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +47.26%
05:09PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 11:40PM	Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation (Insider Monkey) -6.88%
04:05PM	Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call (GlobeNewswire)
Jun-13-25 04:05PM	Alector Provides Executive Leadership Update (GlobeNewswire)
Jun-03-25 08:00AM	Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +7.25%
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.50%
May-08-25 05:30PM	Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +12.50%
04:05PM	Loading…
04:05PM	Alector Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire) -9.48%
Apr-21-25 08:50AM	Alector concludes enrolment in Phase II trial of Alzheimers treatment (Clinical Trials Arena) +5.79%
Apr-17-25 08:00AM	Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimers Disease (GlobeNewswire) -5.95%
Mar-28-25 04:05PM	Alector Provides Executive Leadership Update (GlobeNewswire)
Feb-27-25 12:32PM	Q4 2024 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
02:24AM	Alector Inc (ALEC) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Feb-26-25 05:55PM	Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:53PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 11:01AM	Alector Inc (ALEC) Q4 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-19-25 04:05PM	Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call (GlobeNewswire)
Jan-13-25 08:00AM	Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 (GlobeNewswire)
Nov-27-24 06:50AM	Alector price target lowered to $7 from $35 at H.C. Wainwright (TipRanks)
09:00AM	Loading…
Nov-26-24 09:00AM	Alector stock drops after Alzheimers drug fails in Phase II trial (Clinical Trials Arena) -35.10%
03:44AM	Alector turns to layoffs as Alzheimers drug fails (BioPharma Dive)
Nov-25-24 04:05PM	Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update (GlobeNewswire)
Nov-14-24 04:05PM	Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital (GlobeNewswire) -17.21%
Nov-06-24 05:50PM	Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +7.63%
04:43PM	Alector: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Sep-19-24 08:00AM	Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) (GlobeNewswire) +8.87%
Aug-29-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-23-24 07:19PM	Director Richard Scheller Sells 44,250 Shares of Alector Inc (ALEC) (GuruFocus.com)
Aug-07-24 06:15PM	Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
05:11PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 04:05PM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)
Jul-28-24 08:05AM	Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference 2024 (AAIC ) (GlobeNewswire)
Jul-23-24 07:00AM	Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference (AAIC ) 2024 (GlobeNewswire)
Jun-29-24 08:43PM	Why Did Analysts Give Alector, Inc. (ALEC) a Moderate Buy Rating? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-20-24 07:00AM	Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-10-24 07:00AM	Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform (GlobeNewswire)
Jun-03-24 07:00AM	Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-09-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
May-08-24 11:55PM	ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:25PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:19PM	Alector: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know (Zacks) -8.38%
Feb-28-24 02:02PM	Q4 2023 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
10:13AM	Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-27-24 04:46PM	Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +8.18%
04:23PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-20-24 04:05PM	Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call (GlobeNewswire)
10:00AM	Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline (Zacks)
Feb-08-24 07:00AM	Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease (GlobeNewswire)
06:48AM	Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength? (Zacks)
Feb-07-24 07:00AM	FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire) +5.96%
Jan-25-24 12:00PM	Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-23-24 07:32AM	Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs (InvestorPlace)
Jan-19-24 09:20AM	Alector Announces Closing of Public Offering (GlobeNewswire)
Jan-17-24 08:54AM	Alector Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.01%
Jan-16-24 04:01PM	Alector Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-08-24 01:25PM	Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 (Investor's Business Daily) +7.34%
Dec-05-23 09:55AM	Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet (Zacks)
Nov-28-23 07:00AM	Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs (GlobeNewswire)
Nov-14-23 09:35AM	Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +14.06%
Nov-08-23 07:00AM	Alector to Participate in the Stifel Healthcare Conference (GlobeNewswire) -7.30%
Nov-07-23 06:02PM	Alector: Q3 Earnings Snapshot (Associated Press Finance) +5.12%
05:11PM	Alector Inc (ALEC) Reports Q3 2023 Financial Results with Key Clinical Advancements (GuruFocus.com)
04:05PM	Alector Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 07:00AM	Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire)
Sep-14-23 01:12AM	10% Owner Polaris Venture Management Co. VI, L.L.C. Sells 500,000 Shares of Alector Inc (GuruFocus.com)
Sep-08-23 12:10PM	Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study (Zacks)
Sep-07-23 07:00AM	Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimers Disease (GlobeNewswire) +6.76%
Aug-31-23 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-10-23 09:55AM	Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade (Zacks)
Aug-03-23 05:45PM	Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +32.38%
04:43PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-23 08:30AM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)
Jul-13-23 01:29PM	7 Stocks That AI Says Will Make You a Millionaire by 2025 (InvestorPlace)
Jun-06-23 07:00AM	Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-01-23 07:29AM	Companies Like Alector (NASDAQ:ALEC) Are In A Position To Invest In Growth (Simply Wall St.) -8.20%
May-09-23 09:55AM	Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect? (Zacks)
May-05-23 06:31AM	Benign Growth For Alector, Inc. (NASDAQ:ALEC) Underpins Its Share Price (Simply Wall St.) +10.27%
May-04-23 07:35PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:27PM	Alector: Q1 Earnings Snapshot (AP Finance)
04:05PM	Alector Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 07:00AM	Alector to Participate in the BofA Securities 2023 Healthcare Conference (GlobeNewswire)

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wong-Sarad Grace	Principal Accounting Officer	Sep 02 '25	Sale	2.50	5,910	14,756	103,448	Sep 04 04:33 PM
Berkley Neil Lindsay	Principal Financial Officer	Sep 02 '25	Sale	2.50	15,842	39,554	346,570	Sep 04 04:32 PM
Kenkare-Mitra Sara	President and Head of R&D	Sep 02 '25	Sale	2.50	23,638	59,019	543,339	Sep 04 04:29 PM
Rosenthal Arnon	Chief Executive Officer	Sep 02 '25	Sale	2.50	51,562	128,740	2,350,220	Sep 04 04:27 PM
Neil L. Berkley	Officer	Sep 02 '25	Proposed Sale	2.35	15,426	36,251		Aug 29 06:25 PM
Arnon Rosenthal	Officer	Sep 02 '25	Proposed Sale	2.35	50,242	118,069		Aug 29 06:23 PM
Grace Wong-Sarad	Officer	Sep 02 '25	Proposed Sale	2.35	5,717	13,435		Aug 29 06:20 PM
Sara Kenkare-Mitra	Officer	Sep 02 '25	Proposed Sale	2.35	23,019	54,095		Aug 29 06:17 PM
Hammond Paula	Director	Aug 26 '25	Sale	2.36	14,000	32,998	74,909	Aug 27 06:37 PM
PAULA HAMMOND	Director	Aug 26 '25	Proposed Sale	2.36	14,000	32,997		Aug 26 04:07 PM
MARC GRASSO	Officer	Aug 08 '25	Proposed Sale	2.00	76,446	152,892		Aug 08 05:22 PM
Yaffe Kristine	Director	Jun 20 '25	Sale	1.44	1,000	1,440	95,409	Jun 23 04:05 PM
GRASSO MARC	Chief Financial Officer	Jun 02 '25	Sale	1.34	16,488	22,068	296,072	Jun 04 04:21 PM
Kenkare-Mitra Sara	President and Head of R&D	Jun 02 '25	Sale	1.34	23,890	31,974	512,252	Jun 04 04:19 PM
Rosenthal Arnon	Chief Executive Officer	Jun 02 '25	Sale	1.34	52,087	69,713	2,414,657	Jun 04 04:18 PM
Sara Kenkare-Mitra	Officer	Jun 02 '25	Proposed Sale	1.33	23,020	30,617		May 30 05:10 PM
Marc Grasso	Officer	Jun 02 '25	Proposed Sale	1.33	15,873	21,111		May 30 05:10 PM
Arnon Rosenthal	Officer	Jun 02 '25	Proposed Sale	1.33	50,242	66,822		May 30 05:10 PM
Kenkare-Mitra Sara	President and Head of R&D	Mar 03 '25	Sale	1.47	29,073	42,662	536,142	Mar 05 04:05 PM
Rosenthal Arnon	Chief Executive Officer	Mar 03 '25	Sale	1.47	40,330	59,176	2,466,744	Mar 05 04:05 PM
GRASSO MARC	Chief Financial Officer	Mar 03 '25	Sale	1.47	18,091	26,547	312,560	Mar 05 04:05 PM
Romano Gary	Chief Medical Officer	Mar 03 '25	Sale	1.47	16,306	23,927	332,977	Mar 05 04:05 PM
Arnon Rosenthal	Officer	Mar 03 '25	Proposed Sale	1.64	50,242	82,397		Feb 28 05:05 PM
Gary Romano	Officer	Mar 03 '25	Proposed Sale	1.64	14,306	23,462		Feb 28 05:05 PM
Sara Kenkare-Mitra	Officer	Mar 03 '25	Proposed Sale	1.64	25,516	41,846		Feb 28 05:05 PM
Marc Grasso	Officer	Mar 03 '25	Proposed Sale	1.64	15,873	26,032		Feb 28 05:05 PM
GRASSO MARC	Chief Financial Officer	Dec 02 '24	Sale	2.52	16,489	41,542	330,651	Dec 03 05:40 PM
Rosenthal Arnon	Chief Executive Officer	Dec 02 '24	Sale	2.52	52,172	131,442	2,507,074	Dec 03 05:40 PM
Kenkare-Mitra Sara	President and Head of R&D	Dec 02 '24	Sale	2.52	26,500	66,764	565,215	Dec 03 05:40 PM
Romano Gary	Chief Medical Officer	Dec 02 '24	Sale	2.52	14,892	37,519	349,283	Dec 03 05:40 PM
Gary Romano	Officer	Dec 02 '24	Proposed Sale	2.59	14,306	37,053		Nov 29 03:00 PM
Sara Kenkare-Mitra	Officer	Dec 02 '24	Proposed Sale	2.59	25,465	65,954		Nov 29 03:00 PM
Marc Grasso	Officer	Dec 02 '24	Proposed Sale	2.59	15,842	41,031		Nov 29 03:00 PM
Arnon Rosenthal	Officer	Dec 02 '24	Proposed Sale	2.59	50,142	129,868		Nov 29 03:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALEC

Alector Inc

Upgrade your FINVIZ experience